Remdesivir

CHEMBL4065616 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

602.6 g/mol

LogP

1.9

Phase

4

An antiviral medication originally developed for hepatitis C and Ebola that has been approved for treating COVID-19 and studied for other viral infections. It works by mimicking a building block of RNA to disrupt viral replication.

分子量

602.6000 g/mol

LogP

1.90

TPSA

204.00 Å²

リピンスキーの五則

不適合

治療領域

Pain Management Asthma Insomnia Deep Vein Thrombosis / Pulmonary Embolism Hypertension Chronic Pain HIV/AIDS Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1

InChI

InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1

Molecular Formula

C27H35N6O8P

HBD / HBA

4 / 13

回転可能結合数

14

重原子数

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An antiviral medication originally developed for hepatitis C and Ebola that has been approved for treating COVID-19 and studied for other viral infections. It works by mimicking a building block of RNA to disrupt viral replication.

Yes, Remdesivir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4065616. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 121304016. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Remdesivir PillFYIで

構造

クイックデータ

分子式: C27H35N6O8P
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.